RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MORABITO A
Collezione AO Ordine Mauriziano

Items : 7

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]. in ESMO open / ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1.

2022
AO Ordine Mauriziano

Cantini L; Mentrasti G; Lo Russo G; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; La Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. in ESMO open / ESMO Open. 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub 2022 Feb 3.

2022
AO Ordine Mauriziano

Cantini L; Mentrasti G; Russo GL; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. in BMC cancer / BMC Cancer. 2021 May 14;21(1):549. doi: 10.1186/s12885-021-08323-4.

2021
AO Ordine Mauriziano

Gallo C; Di Maio M; Schettino C; Gravina A; Di Liello R; Mancuso G; Morgillo F; Della Corte CM; Esposito G; Spagnuolo A; Palumbo G; Maione P; Gebbia V; Ciardiello F; Morabito A; Gridelli C; Arenare L; Gargiulo P; Perrone F; Piccirillo MC;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. in Clinical lung cancer / Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1.

2018
AO Ordine Mauriziano

Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S; et alii...

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2017 Jun;108:15-21. doi: 10.1016/j.lungcan.2017.02.016. Epub 2017 Feb 27.

2017
AO Ordine Mauriziano

Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C;